**Core tip:** Despite the limited number of subjects, the longitudinal experimental design with a healthy reference group reveals insights into childhood metabolic status in relation to growth and disease. Metabolite profiling of urine samples collected non-invasively enables identification and monitoring of biochemical signatures linked to metabolic and nutritional requirements in pediatric populations with inflammatory bowel disease (IBD). In the present study, a distinct biochemical process related to glutathione, glycine and bile acid metabolism distinguished children with IBD from healthy matched controls.

INTRODUCTION
============

The use of systems biology-oriented technologies (*e.g*., metabonomics, proteomics, genomics and microbiomics) redefines disease understanding and phenotyping of clinical characteristics in medical disorders such as in gastrointestinal deregulations\[[@B1],[@B2]\]. This is particularly relevant for inflammatory bowel disease (IBD), where a systems-level approach of the pathogenesis can inform novel, integrated multiple pathway- therapies and contribute to the development of personalized disease management\[[@B2]\].

The prevalence of IBD has markedly increased over the years, with 25% of the population developing the disease during childhood and adolescence\[[@B2],[@B3]\]. In addition to the clinical and immunological features of the disease, pediatric patients suffer from additional growth failure and delayed puberty\[[@B3]-[@B5]\]. During this critical period, IBD children can suffer from malnutrition, which is related to reduced energy intake, malabsorption and thus loss of nutrients, and inflammation\[[@B3],[@B6]-[@B9]\]. These factors mainly contribute to delayed growth and physiological maturation. Moreover, there is a great lack of knowledge on how to address metabolic and nutritional requirements in these children and adolescents\[[@B5]\]. The use of omics-technologies for holistic molecular phenotyping over time can generate the data for a systems-level view of metabolic processes associated with growth and development of children in relation to the changing physiology in infancy and childhood\[[@B5]\].

Amongst the omic technologies, metabonomics enables the study of physiological regulatory processes through the simultaneous analysis of a large range of biochemical species\[[@B2],[@B10]-[@B13]\]. The technology is based on either targeted or untargeted profiling of small biomolecular compounds in tissues and biological fluids, such as blood, urine or saliva. Metabolites profiles can be generated through the use of proton nuclear magnetic resonance (^1^H NMR) spectroscopy or mass spectrometry (MS) combined eventually with chromatographic separation. Recently, we have applied ^1^H NMR based profiling to urine samples from IBD and healthy matched children and highlighted differences related to central energy metabolism, as well as amino acid and gut microbial metabolism in relation to growth and disease activity\[[@B14]\]. In particular, we showed how specific metabolite patterns in urine could help monitoring metabolic status in relation to disease state. In the present study, we continue our metabolic exploration by targeting host-gut microbial metabolites in urine samples from the same children, including the aromatic amino acid and bile acid co-metabolites - two well-established examples of transgenomic metabolic cross-talk. For this purpose, we applied liquid chromatography (LC) and gas chromatography (GC) coupled to MS-based metabolite profiling. We here report urinary metabolic phenotypes specific to IBD children compared to healthy matched controls. Advanced clinical and anthropometric phenotyping was also performed on these IBD children over the course of one year of standard-care disease management (0, 6 and 12 mo) to identify relationships between biochemical processes and anthropometric phenotypes.

MATERIALS AND METHODS
=====================

Ethical considerations
----------------------

This clinical study was approved by the Ethical Committee of the University of Lausanne, Switzerland (protocol 69/10), and conducted in the Pediatric Gastroenterology outpatient clinic of the University Hospital of Lausanne, Switzerland. Informed written consent was obtained from the patients and their parents.

Recruitment of participants
---------------------------

Eligible patients were aged between 10 and 18 years old, with a diagnosis of Crohn's disease (CD) or ulcerative colitis (UC), confirmed according to international criteria\[[@B15]\]. IBD subjects were assessed at baseline (T0), after 6 (T6) and 12 mo (T12), respectively. All patients were in remission and underwent therapeutical management of the disease according to recommended drugs. To be noted that none was treated with enteral nutrition and no endoscopy was performed to assess mucosal inflammation. Control healthy subjects were recruited among the general pediatric population. They were matched for age, pubertal stage and gender to the IBD subjects. They had neither chronic inflammatory disease nor family history of inflammatory bowel. Anthropometric and clinical data and urine samples for metabolic analyses were collected at each time point.

Anthropometric assessment
-------------------------

Body weight, height and BMI were measured under standard clinical practice, as previously reported\[[@B14]\]. Height velocity was calculated as the amount of growth in centimeters divided by the time interval between measurements in years. All values were expressed in *z*-scores\[[@B16],[@B17]\]. Pubertal stage was assessed according to Tanner score\[[@B18]\].

Body composition
----------------

Bioimpedance analysis (BIA) was performed using Body Impedance Analyser Akern (Florence, Italy), as previously reported\[[@B14]\]. Fat free mass in kg (FFM) was then calculated using the software BodyGram Pro^®^ supplied by the manufacturer \[which uses weight, age, and an impedance index (height^2^/resistance)\]\[[@B19],[@B20]\]. Percentage of FFM (%FFM) was calculated by dividing FFM with the body weight of the subject expressed in kg.

Disease activity in patients with IBD
-------------------------------------

Disease activity was scored using the Pediatric Crohn's Disease Activity Index (PCDAI)\[[@B21]\] for CD, a 100 point scale where a score \> 30 indicates severe disease, and the Pediatric Ulcerative Colitis Activity Index (PUCAI)\[[@B22]\] for UC, a 85 points scale where a score \> 35 indicates severe disease. Remission was defined as PCDAI or PUCAI score lower than 10. No endoscopic control was performed since all patients were in remission.

Blood and stool markers
-----------------------

Inflammatory markers \[Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP)\], urea, and growth factors \[Insulin-like Growth Factor 1 and Insulin-like Growth Factor-Binding Protein 3, expressed in *z*-scores\] were obtained after a fasting period of at least 6 h. Fecal calprotectin was measured and a cut-off value of 275 μg/g was set to determine possible relapse of disease\[[@B23]\].

Dietary intake
--------------

All subjects underwent a 24-h food recall with the help of a questionnaire showing pictures of different sizes of plates for the different foods with the same examiner (dietician TC). Qualitative and quantitative analyses were made using the software Prodi 5.8 Expert. Daily intake was expressed as kcal per day.

Resting energy expenditure
--------------------------

Resting energy expenditure (REE, kcal) was measured using Quark RMR (Cosmed, pulmonary function equipment, Delta Medical, Italy), as previously reported\[[@B14]\].

Sample collection
-----------------

Morning spot urine samples were collected at baseline for all subjects, at the 6-mo and 12-mo visit for IBD patients only. Urine samples (1 mL) were collected by means of sterile plastic tubes, and stored at -80 °C, prior to analysis.

Bile acid analysis
------------------

**Chemicals:** All of the 57 bile acid standards were obtained from Steraloids Inc. (Newport, RI) and TRC Chemicals (Toronto, ON, Canada), and 9 stable isotope- labeled standards were obtained from C/D/N Isotopes Inc. (Quebec, Canada) and Steraloids Inc. (Newport, RI).

Methanol (Optima LC-MS), acetonitrile (Optima LC-MS) and formic acid (Optima LC-MS) were purchased from Thermo-Fisher Scientific (FairLawn, NJ). Ultrapure water was produced by a Mill-Q Reference system equipped with a LC-MS Pak filter (Millipore, Billerica, MA).

**Sample preparation:** At the time of analysis, samples were thawed on ice-bath to diminish biochemical degradation. 100 μL of urine or standard solution of a bile acid-free matrix was directly lyophilized to dry powder using a freeze dryer. The residue was reconstituted in 50 μL of mobile phase B (acetonitrile/methanol = 95/5, v/v) and 25 μL of mobile phase A (water with formic acid, pH = 3.25), and centrifuged at 13500 g and 4 °C for 20 min. The supernatant was transferred to a 96-well plate for LC-MS analysis and the injection volume was 10 μL.

**Data generation and analysis:** An ultra-performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS) system (ACQUITY UPLC-Xevo TQ-S, Waters Corp., Milford, MA) was used to quantitate bile acids in the human urine samples based on our previously published protocols\[[@B24],[@B25]\]. The raw data was processed using the TargetLynx application manager (Waters Corp., Milford, MA) to obtain calibration equations and the measured concentration of each bile acid in the samples. The quality control samples were prepared with the addition of bile acid stock solutions to blank matrix at a final concentration of 10, 100, or 1000 nmol/L. The quality control samples (four QCs in a 96-well plate) were prepared along with the real samples, and injected at regular intervals to allow evaluating overall process variability and monitoring platform performance. Each kit plate is ideal for the analysis of 84 samples, 8 calibrators (CAL0 = blank matrix), and 4 QCs (QC1 = 10 nmol/L, QC2 and QC3 = 100 nmol/L, and QC4 = 1000 nmol/L). The noise baseline was established from reagent blank measurement and any metabolite with signal to noise ratio ≤ 3.0 is rejected from statistical analysis. The relative standard deviation (RSD) for the lower concentration metabolites in the reference standard mixture was less than 30% and the RSD for the higher concentration metabolites was better than 15% for each batch of sample analysis (100 injections for LC-MS analysis).

GC-MS based metabonomics
------------------------

**Chemicals:** The derivatization reagents methyl and ethyl chloroformate, as well as HPLC grade solvents including methanol, ethanol, chloroform and pyridine were purchased from Sigma-Aldrich (St. Louis, MO, United States). Sodium hydroxide, sodium bicarbonate and anhydrous sodium sulfate were of analytical grade and obtained from JT Baker Co. (Phillipsburg, NJ). All standard compounds were commercially purchased from Sigma-Aldrich and Nu-Chek Prep (Elysian, MN, United States). Ultrapure water was produced by Milli-Q system (Millipore, Billerica, MA).

**Extraction of metabolites from human urine:** Urine samples were thawed on ice and prepared as follows: urine sample (100 μL) was added into a silanized glass vial and lyophilized directly under low temperature (-40 °C) by a Labconco freeze-dryer. The solids from urine samples after lyophilization process were sealed and stored at -80 °C for subsequent automated derivatization assay.

**Automated chloroformate derivatization and GC/MS analysis:** The sample derivatization protocols with MCF and ECF was based on the method described by Villas-Bôas et al\[[@B26]\] and our previously published procedures\[[@B27]\], with minor modifications. For routine large-scale sample analysis, sample derivatization and all liquid handling were performed by a commercially available robotic workstation (GERSTEL MPS Autosampler).

**Gas chromatography/time-of-flight mass spectrometry analysis:** Samples were randomly analyzed by GC/TOFMS (Agilent 6890N gas chromatography coupled with a LECO Pegasus HT time-of-ﬂight mass spectrometer) using our optimized conditions in this study. One microliter of each derivatized sample was injected splitless into a DB-5 ms capillary column (30 m × 0.25 mm i.d., 0.25 μm ﬁlm thickness; (5%-phenyl)-methylpolysiloxane bonded and cross-linked; Agilent JW Scientiﬁc, Folsom, CA) , with helium as the carrier gas at a constant ﬂow rate of 1.0 mL/min. The solvent delay time was set to 2.5 min. The optimized temperature gradient was the following: 45 °C held for 1 min, then increased at a rate of 20 °C/min up to 260 °C and 40 °C/min to 320 °C/min, then held there for 2 min. The total time of analysis was 15.25 min. The temperature of injection, transfer interface and ion source were set to 270, 270 and 220 °C, respectively. Electron impact ionization (70 eV) at full scan mode (m/z 38-650) was used. The acquisition rate was 20 spectra/s.

**Data processing:** Non-processed MS files from GC/TOFMS analysis were exported in NetCDF format to ChromaTOF (v4.50, Leco Co., CA, United States) and subject to the following processing including baseline correction, smoothing, noise reduction, deconvolution, library searching, and area calculation. Compound identiﬁcation was performed by comparing both MS and Kovats-RI with reference standards in author-constructed two alkyl chloroformates derivatives databases, with a similarity of more than 70%.

Statistical analysis
--------------------

Chemometric analysis was performed on clinical and metabonomics data using the software package SIMCA-P+ (version 12.0, Umetrics AB, Umeå, Sweden). Principal component analysis (PCA) and a modification of Partial Least Squares Regression (PLSR) that removes all information orthogonal to the response variable during the fitting process were employed. This variant, Orthogonal Projection to Latent Structures (O-PLS)\[[@B28]\] provides sparser models (improving their interpretability) with the same degree of fit as PLSR. For group comparison, multivariate data analysis was performed using O-PLS-discriminant analysis (OPLS-DA). To highlight the weight of individual variables in the model, Variable Importance in the Projection (VIP) was used, with a value above 1 used as a threshold by convention. In addition, a Pearson correlation coefficient with a p-value significant at 95% confidence interval (*e.g*., with *n* = 46, *r* = 0.40). Metabolic pathway analysis was conducted by performing a metabolite set enrichment analysis, using the web-based MetaboAnalyst 3.0 tool\[[@B29]\], to the list of influential metabolites obtained through multivariate data analysis.

RESULTS
=======

Clinical and metabolite parameters of IBD and healthy subjects
--------------------------------------------------------------

The patient information has been reported previously\[[@B14]\]. Briefly, the study population was composed of 21 pediatric IBD patients and 27 age and gender matched healthy children. IBD children were monitored over one year period, with a baseline visit, and follow-up visits after 6 and 12 mo. CD patients showed lower *z*-scores for body weight, height, BMI and resting energy expenditure at baseline and at follow-up visits\[[@B14]\]. Targeted MS metabolic profiling detected and quantified 69 metabolites by GC-MS and 30 bile acid species in urine. We report in Table [1](#T1){ref-type="table"} the urinary concentrations of all the metabolites at baseline for health and IBD children. Using this set of 99 metabolites, we have applied a Metabolite Set Enrichment Analysis\[[@B29]\] to summarize the main metabolic pathways captured by our systems approach. As reported in Figure [1](#F1){ref-type="fig"}, the analysis provides a comprehensive approach to generate insights in relation to protein biosynthesis, bile acid biosynthesis, aspartate, alanine, glutathione, urea, ammonia and citric acid (TCA) cycles.

###### 

Urinary metabolite overview in healthy and inflammatory bowel disease children at baseline

  **Metabolites**                               **Healthy**             **IBD baseline**        ***P* value**
  --------------------------------------------- ----------------------- ----------------------- ---------------
  2-hydroxybutyric acid                         324.2 ± 228.5           401.9 ± 306.8           0.335
  3-(3-hydroxyphenyl)-3-hydroxypropanoic acid   85.1 ± 242.2            240.6 ± 488.6           0.168
  3-aminoisobutanoic acid                       7278 ± 8267.9           12302.4 ± 15388.8       0.166
  3-hydroxyisovaleric acid                      12675.2 ± 14366.2       13929.9 ± 6198.6        0.722
  3-hydroxyphenylacetic acid                    6618.8 ± 7906.4         3579.7 ± 4269.6         0.134
  3-methyl-2-oxovaleric acid                    12049.5 ± 5596.6        13764.2 ± 4303.2        0.269
  4-hydroxybenzoic acid                         1659.4 ± 835.8          1660.6 ± 735.9          0.996
  4-hydroxycinnamic acid                        1749 ± 2142.3           4655.3 ± 5127.8         0.013
  Adipic acid                                   5757.5 ± 3488.3         6806.6 ± 6403.6         0.485
  Alpha-hydroxyisobutyric acid                  7514.4 ± 4562.7         10645.1 ± 5098.4        0.036
  Aminoadipic acid                              23462.2 ± 13757.6       24927 ± 13309.2         0.722
  Beta-alanine                                  3554.8 ± 2690.1         3730.4 ± 2705.5         0.830
  Butyric acid                                  594 ± 329.1             754.4 ± 551             0.230
  Caproic acid                                  337.3 ± 393.0           423.4 ± 412.3           0.480
  Caprylic acid                                 113.7 ± 233.6           114.2 ± 335.3           0.996
  Cis-aconitic acid                             126743 ± 94692.1        217610 ± 154442.2       0.019
  Citraconic acid                               1487.4 ± 719.3          1877.1 ± 529.1          0.051
  Citramalic acid                               13454 ± 11088.9         29200.5 ± 23835.6       0.005
  Citric acid                                   1521627.7 ± 1117692.9   2010896.5 ± 1470323.3   0.211
  Dodecanoic acid                               76 ± 118.3              95.1 ± 230.1            0.718
  Dopamine                                      25594.1 ± 15600.7       46132.8 ± 4070.5        0.000
  Ethylmethylacetic acid                        354.4 ± 161.6           300 ± 108.3             0.208
  Fumaric acid                                  4447.5 ± 5258.8         8002.2 ± 5704.2         0.036
  Gamma-aminobutyric acid                       8011.9 ± 2433.5         9501.4 ± 2144.3         0.038
  Glutaric acid                                 6350.9 ± 2956.9         8011.9 ± 3153           0.077
  Glyceric acid                                 24294.2 ± 44555.4       34244.8 ± 54085.6       0.503
  Glycine                                       90591.2 ± 73998.7       150330 ± 121868.4       0.048
  Glycolic acid                                 85357.2 ± 57207.8       98641.7 ± 50868.8       0.424
  Hippuric acid                                 579641.8 ± 409879.0     435904.9 ± 374381.5     0.234
  Homogentisic acid                             395731.6 ± 236443.5     706581.6 ± 61533.7      0.000
  Indoleacetic acid                             58737.6 ± 40343.9       107584.7 ± 107498.1     0.040
  Isocitric acid                                418285.5 ± 291898.4     767013.4 ± 476267.9     0.004
  Isovaleric acid                               96.7 ± 125.3            53.8 ± 103.4            0.228
  Itaconic acid                                 7961.3 ± 6523.3         12949.6 ± 11408.9       0.071
  L-2-hydroxyglutaric acid                      14028.4 ± 7911.3        25645.4 ± 16050.4       0.003
  L-alanine                                     26378.1 ± 18928.9       36445.6 ± 16618.3       0.070
  L-alpha-aminobutyric acid                     1777.6 ± 1093.0         1826.9 ± 1158.2         0.885
  L-asparagine                                  16684.8 ± 15672.4       25642.5 ± 14904.9       0.059
  L-aspartic acid                               2801.2 ± 833.5          3708.1 ± 1242           0.005
  L-cysteine                                    7833.5 ± 5012.7         12771 ± 4681.6          0.002
  L-glutamic acid                               18551.2 ± 13284.8       29044.7 ± 18203.4       0.030
  L-histidine                                   300484.2 ± 313800.2     328182 ± 163648.8       0.726
  L-isoleucine                                  1874.2 ± 954.0          3149.4 ± 1492.8         0.001
  L-leucine                                     4028.1 ± 3120.4         5677.4 ± 4266.7         0.141
  L-lysine                                      38409.7 ± 46071.6       46194.7 ± 36720.6       0.545
  L-methionine                                  1236.4 ± 696.3          2195.1 ± 1206.4         0.002
  L-phenylalanine                               18545.8 ± 14394.6       26167 ± 13952.9         0.082
  L-proline                                     1131.5 ± 512.2          2020.9 ± 1099.8         0.001
  L-tryptophan                                  26500.2 ± 13737.3       33639.1 ± 12697.3       0.082
  L-tyrosine                                    63971.6 ± 55716.2       84163.3 ± 63553.6       0.264
  L-valine                                      4892.5 ± 2641.4         7343.2 ± 3296.4         0.008
  Malonic acid                                  493 ± 486.4             663.3 ± 547.4           0.277
  Methylsuccinic acid                           1655.6 ± 861.4          2484.1 ± 1188.1         0.009
  N-acetyltryptophan                            82232.1 ± 58726.0       112567.4 ± 56382.5      0.088
  Nicotinic acid                                1293.3 ± 1311.8         2104.1 ± 1204           0.039
  Ornithine                                     7948.8 ± 2592.9         11968.9 ± 4307.9        0.000
  Ortho-hydroxyphenylacetic acid                1265.1 ± 770.7          1915.5 ± 1233.6         0.035
  Oxoglutaric acid                              23844.7 ± 20947.4       34260.9 ± 33676.2       0.209
  Phenol                                        266.1 ± 168.1           282 ± 165.2             0.753
  Phenylacetic acid                             3055.4 ± 2506.3         5635.2 ± 5749.6         0.048
  Phenyllactic acid                             729.1 ± 1365.9          2726.7 ± 2958.9         0.004
  P-hydroxyphenylacetic acid                    8991.4 ± 5587.6         16438.3 ± 9973.0        0.003
  Pimelic acid                                  2203 ± 1453.7           3343.5 ± 1728.2         0.021
  Pyroglutamic acid                             39396.7 ± 14482.8       52204.6 ± 19506.9       0.015
  Salicyluric acid                              3342.8 ± 1712.7         4135.9 ± 1498.5         0.112
  Suberic acid                                  8538.8 ± 5594.7         12987.5 ± 5378.1        0.010
  Succinic acid                                 23748.9 ± 18864.3       34383.7 ± 30189.9       0.154
  Tartaric acid                                 5156.1 ± 9387.3         11376.5 ± 27499.5       0.291
  Vanillic acid                                 2838.1 ± 5734.4         3091.8 ± 3028.7         0.861
  12_ketoLCA                                    11.5 ± 2.4              13.5 ± 4.5              0.072
  3_DHCA                                        13.4 ± 11.9             17 ± 15.7               0.396
  7_DHCA                                        145.5 ± 276.1           267.1 ± 439.7           0.267
  7_ketoLCA                                     10.9 ± 2.9              13.6 ± 7.2              0.093
  Beta-CA                                       12.9 ± 10.4             26.1 ± 27.0             0.029
  Beta-UCA                                      42.1 ± 93.8             114.8 ± 168.0           0.074
  CA                                            182.3 ± 237.0           266 ± 322.5             0.327
  CDCA                                          21.9 ± 9.7              24.9 ± 11.2             0.346
  CDCA_24GLN                                    79.6 ± 49.1             168 ± 151.2             0.008
  CDCA_3GLN                                     64.1 ± 45.2             149.1 ± 105.5           0.001
  DCA                                           45.2 ± 28.7             40.2 ± 31.0             0.588
  GCA                                           84.4 ± 43.2             151.8 ± 162.6           0.051
  GCDCA                                         39.8 ± 20.6             51.3 ± 25.1             0.105
  GDCA                                          34.5 ± 33.4             30.4 ± 15.9             0.627
  GHCA                                          36.7 ± 17.6             49.4 ± 41.5             0.171
  GHDCA                                         14.4 ± 2.6              12.3 ± 0.6              0.002
  GLCA                                          8.4 ± 5.7               4.8 ± 4.2               0.026
  GUDCA                                         15.5 ± 17.5             39.5 ± 47.9             0.025
  HCA                                           10.3 ± 1.5              10.5 ± 1.5              0.768
  HDCA                                          17.1 ± 35.3             15.2 ± 10.2             0.820
  LCA                                           19.1 ± 6.6              22.4 ± 32.6             0.621
  LCA_S                                         22.5 ± 11.9             22.6 ± 22.2             0.989
  NORCA                                         154.3 ± 116.0           181.4 ± 133.4           0.476
  NORDCA                                        9.2 ± 1.5               9.3 ± 0.4               0.679
  TCA                                           24.6 ± 8.2              26 ± 11.9               0.652
  TCDCA                                         23.4 ± 7.7              23.4 ± 5.6              0.99
  THCA                                          13.7 ± 3.0              18.4 ± 11.4             0.052
  TUDCA                                         8.2 ± 1.6               9 ± 1.2                 0.099
  UCA                                           108.2 ± 135.4           268.4 ± 310.0           0.024
  UDCA                                          11.6 ± 1.4              13.1 ± 2.0              0.008

Metabolite data are reported as mean ± SD of their urinary concentrations, in ng/mL for GC-MS metabolites, and nmol/L for the bile acids. *P* value from standard *t*-test is reported as a qualitative indicator for metabolic variations between the two groups of children. 12-KetoLCA: 12-ketolithocholic acid; 3_DHCA: 3-dehydrocholic acid; 7_DHCA: 7-dehydrocholic acid; 7_KetoLCA: 7-ketolithocholic acid; 3βCA: 3β-Cholic acid; βUCA: β-ursocholic acid; CA: Cholic acid; CDCA: Chenodeoxycholic acid; CDCA_24GLN: Chenodeoxycholic acid 24-Acyl-β-D-glucuronide; CDCA_3GLN: Chenodeoxycholic acid-3-β-D-glucuronide; DCA: Deoxycholic acid; GCA: Glycocholic acid; GCDCA: Glycochenodeoxycholic acid; GDCA: Glycodeoxycholic acid; GHCA: Glycohyocholate; GHDCA: Glycohyodeoxycholate; GLCA: Glycolithocholate; GUDCA: Glycoursodeoxycholic acid; HCA: γ-muricholic acid/hyocholic acid; HDCA: α-hyodeoxycholic acid; LCA: Lithocholic acid; LCA_S: Lithocholic acid 3 sulfate; NORCA: Nor cholic acid; NORDCA: 3α,12α-dihydroxynorcholanate/23-nordeoxycholic acid; TCA: Taurocholic acid; TCDCA: Taurochenodeoxycholic acid; THCA: Taurohyocholate; TUDCA: Tauroursodeoxycholic acid; UCA: Ursocholic acid; UDCA: Ursodeoxycholic acid.

![Summary plot for over representation analysis of urinary metabolites, using metabolite set enrichment analysis.](WJG-23-3643-g001){#F1}

Urine biochemical composition illustrates metabolic differences between IBD and healthy children
------------------------------------------------------------------------------------------------

Due to sample dilution, the urine sample from hone healthy control was discarded from analysis by MS metabonomics. Initial inspection of the main source of variations between the samples was performed using principal component analysis (PCA). A model was generated using four principal components, explaining 30%, 8%, 6% and 4% of the total variance, respectively. The sources of variance captured by the third and fourth components highlighted a separation of the urine of healthy children from the IBD patients, irrespective of their time of collection.

Using OPLS-DA, we first assessed the occurrence of urinary signatures discriminating the urine samples from healthy subjects and IBD patients. A first OPLS-DA model generated on urine samples collected, with one predictive and one orthogonal component, described statistically robust metabolic differences at baseline. This is observed through the model parameters R^2^X = 0.37, R^2^Y = 0.72, Q^2^Y = 0.47, where R^2^X is the explained variance in the urine metabolic profile, R^2^Y the explained group variance and Q^2^Y an indicator of mode robustness. We further tested the reproducibility of the metabolic differences by comparing the urine collected from IBD patients after 6 and 12 mo of standard disease management with the reference samples from the healthy children. The models generated with one predictive and one orthogonal component were significant at 6 mo (R^2^X = 0.36, R^2^Y = 0.67, Q^2^Y = 0.41) and at 12 mo (R^2^X = 0.38, R^2^Y = 0.73, Q^2^Y = 0.47).

Examination of the three models resulted in the identification of consistent urinary metabolic differences between the group of healthy subjects and IBD patients. In Table [2](#T2){ref-type="table"}, we report metabolites that were significantly different in at least two of the models with VIP \> 1.0, and their corresponding Pearson correlation coefficient. These differences described variations in relation to glutathione metabolism (glycine, glutamate, pyroglutamate and cysteine), urea (fumarate, arginine, alanine, aspartate, and ornithine) and TCA (fumarate, isocitrate, 2-hydroxyglutaric acid, and methylsuccinic acid) cycles, catecholamines (dopamine and tyrosine), several amino acids (*e.g*., phenylalanine, tyrosine, proline, and glutamate), aromatic acid and bile acid bacterial co-metabolism.

###### 

Overview of influential metabolites discriminating healthy and inflammatory bowel disease patients

  **Metabolic pathways**         **Metabolites**              **Comparison healthy - IBD subjects at**                               
  ------------------------------ ---------------------------- ------------------------------------------ ------ ------ ------ ------ ------
  Tca cycle                      Methylsuccinic acid          1.3                                        0.4    1.2    0.2    1.0    0.1
  Fumaric acid                   1.2                          0.3                                        1.0    0.3    1.1    0.2    
  2-hydroxyglutaric acid         1.4                          0.5                                        1.3    0.4    1.3    0.3    
  Isocitric acid                 1.4                          0.4                                        1.3    0.3    1.2    0.2    
  Glutathione metabolism         Cysteine                     1.5                                        0.5    1.2    0.3    1.4    0.4
  Glycine                        1.2                          0.3                                        1.3    0.3    1.2    0.3    
  Glutamic acid                  1.2                          0.3                                        1.3    0.3    1.2    0.3    
  Pyroglutamic acid              1.3                          0.4                                        1.3    0.3    1.0    0.1    
  Neurostransmitter metabolism   Gamma-Aminobutyric acid      1.2                                        0.3    1.2    0.3    1.0    0.1
  Dopamine                       1.6                          0.7                                        1.8    0.6    1.1    0.4    
  Homogentisic acid              1.6                          0.7                                        1.8    0.6    1.1    0.4    
  Bacterial metabolism           3-hydroxyphenylacetic acid   1.3                                        -0.5   1.2    -0.4   1.1    -0.3
  Hippuric acid                  1.0                          -0.3                                       1.2    -0.4   1.6    -0.5   
  Indoleacetic acid              1.3                          0.4                                        1.3    0.4    1.0    0.1    
  4-hydroxyphenylacetic acid     1.3                          0.5                                        1.1    0.3    1.0    0.2    
  Phenyllactic acid              1.1                          0.4                                        0.6    0.2    1.4    0.5    
  Other                          Salicyluric acid             1.2                                        0.4    0.9    0.2    1.0    0.4
  Dicarboxylic acid metabolism   Suberic acid                 1.3                                        0.5    1.5    0.5    1.1    0.3
  Bile acids                     Beta-UCA                     1.5                                        0.6    1.0    0.4    0.7    0.2
  GUDCA                          1.3                          0.5                                        1.5    0.5    1.9    0.7    
  THCA                           1.0                          0.4                                        0.3    0.1    1.3    0.4    
  UDCA                           1.4                          0.6                                        1.7    0.6    1.8    0.6    
  GHDCA                          1.3                          -0.5                                       1.3    -0.5   1.0    -0.3   
  Amino acid metabolism          Aspartic acid                1.3                                        0.4    0.8    0.2    1.4    0.4
  Histidine                      1.1                          0.3                                        1.1    0.2    0.9    0.1    
  Isoleucine                     1.5                          0.4                                        1.6    0.4    1.3    0.2    
  Methionine                     1.5                          0.5                                        1.6    0.5    1.4    0.4    
  Phenylalanine                  1.3                          0.3                                        1.2    0.2    1.1    0.1    
  Proline                        1.4                          0.5                                        1.4    0.4    1.2    0.3    
  Tryptophan                     1.2                          0.3                                        1.2    0.2    1.1    0.2    
  Tyrosine                       1.1                          0.2                                        1.0    0.1    1.0    0.1    
  Valine                         1.3                          0.3                                        1.3    0.3    1.1    0.1    
  N-acetyltryptophan             1.2                          0.3                                        1.2    0.2    1.1    0.2    
  Ornithine                      1.4                          0.5                                        1.7    0.5    1.7    0.5    
  Aminoadipic acid               1.0                          0.0                                        1.2    0.3    1.1    0.1    

IBD: Inflammatory bowel disease; TCA: Taurocholic acid; bUCA: Beta-ursocholic acid; GUDCA: Glycoursodeoxycholic acid; THCA: Taurohyocholate; UDCA: Ursodeoxycholic acid; GHDCA: Glycohyodeoxycholate.

Whilst most of the metabolites appeared to be excreted in higher concentrations in IBD patients, only 3 metabolites showed reduced concentrations, namely hippurate, 3-hydroxyphenylacetate and the bile acid glyco-hyodeoxycholic acid (GHDCA).

We further assessed if some urinary metabolites were specific to the few UC patients. OPLS-DA models were generated to compare the subjects at the different time points. The models generated with one predictive and two orthogonal components were significant at baseline (R^2^X = 0.42, R^2^Y = 0.94, Q^2^Y = 0.34), at 6 mo (R^2^X = 0.48, R^2^Y = 0.94, Q^2^Y = 0.55) and at 12 mo (R^2^X = 0.50, R^2^Y = 0.95, Q^2^Y = 0.55). Only three metabolites showed pattern differentiating UC from CD patients consistently over time, including higher urinary concentrations of deoxycholic acid (DCA), 7-ketolithocholic acid and beta-ursocholic acid (βUCA) in urine from UC patients (Table [3](#T3){ref-type="table"}).

###### 

Overview of influential metabolites discriminating ulcerative colitis and Crohn's disease patients

  **Comparison UC - CD subjects at metabolites**   **Baseline**   **6 mo**   **12 mo**               
  ------------------------------------------------ -------------- ---------- ----------- ----- ----- -----
  DCA                                              1.6            0.5        1.4         0.5   0.8   0.2
  7-ketoLCA                                        1.1            0.3        1.2         0.4   1.8   0.5
  Beta-UCA                                         0.3            0.1        2.0         0.7   1.0   0.3

UC: Ulcerative colitis; CD: Crohn's disease; DCA: Deoxycholic acid; 7_KetoLCA: 7-ketolithocholic acid; bUCA: Beta-ursocholic acid.

Finally, we explored urinary metabolic signatures linked to clinical and anthropometric endpoints in the IBD population. An O-PLS regression approach was applied using cross-validation by subjects, since clinical and metabonomics data were generated from each subject at 3 different time points. Some relationships between urinary metabolite profiles and anthropometric features were modeled, but not in relation to disease index (Q^2^Y \< 0) or inflammatory status (CRP, calprotectin, Q^2^Y \< 0). Statistically significant associations were modeled in relation to BMI (R^2^X = 0.40, R^2^Y = 0.82, Q^2^Y = 0.35), BMI-z scores (R^2^X = 0.40, R^2^Y = 0.83, Q^2^Y = 0.29), body weight (R^2^X = 0.43, R^2^Y = 0.74, Q^2^Y = 0.15), % of fat mass (R^2^X = 0.39, R^2^Y = 0.83, Q^2^Y = 0.36). A conservative approach was applied for selecting the most influential metabolites, namely using the VIP threshold \> 1.0 and a r value significance at 95%CI (*e.g., r* \> 0.265 or *r* \< -0.265). A consolidated data overview is reported in Table [4](#T4){ref-type="table"} for the relevant anthropometric parameters and metabolites. Similar urinary metabolite patterns could be ascribed to the body composition parameters, including bile acids, amino acids and TCA cycle intermediates, as well as some dietary/gut microbial related metabolites (Table [4](#T4){ref-type="table"}).

###### 

Overview of metabolites associated with anthropometric parameters

  **Metabolic pathways**   **Metabolites**              **Anthropometric parameters**                                                
  ------------------------ ---------------------------- ------------------------------- ------- ------ ------- ------ ------- ------ ------
  TCA cycle                L-2-hydroxyglutaric acid     0.41                            1.57    0.22   1.23    0.29   1.36    0.14   1.07
  Oxoglutaric acid         0.48                         1.66                            0.29    1.32   0.35    1.41   0.13    0.91   
  Succinic acid            0.39                         1.50                            0.17    1.12   0.24    1.24   0.10    0.98   
  Bacterial metabolism     3-hydroxyphenylacetic acid   0.44                            1.49    0.27   1.20    0.29   1.22    0.23   1.07
  Hippuric acid            0.32                         1.27                            0.27    1.27   0.28    1.26   0.19    1.03   
  Phenol                   0.44                         1.42                            0.42    1.57   0.48    1.68   0.26    1.10   
  Bile acids               12_ketoLCA                   0.34                            1.13    0.41   1.53    0.40   1.40    0.39   1.48
  DCA                      0.48                         1.62                            0.48    1.82   0.50    1.76   0.52    2.02   
  GDCA                     0.48                         1.58                            0.49    1.85   0.47    1.66   0.53    2.01   
  GHDCA                    0.38                         1.28                            0.49    1.81   0.42    1.47   0.45    1.69   
  GLCA                     0.19                         0.87                            0.32    1.28   0.30    1.17   0.43    1.69   
  LCA                      0.35                         1.16                            0.37    1.40   0.34    1.20   0.41    1.57   
  NORDCA                   0.37                         1.25                            0.45    1.65   0.44    1.54   0.57    2.13   
  TUDCA                    -0.12                        0.81                            -0.32   1.35   -0.31   1.27   -0.43   1.65   
  UCA                      -0.30                        0.96                            -0.38   1.39   -0.33   1.16   -0.35   1.42   
  UDCA                     -0.11                        0.70                            -0.42   1.60   -0.38   1.39   -0.44   1.65   
  Amino acid metabolism    Aminoadipic acid             0.36                            1.41    0.22   1.20    0.25   1.23    0.17   1.06
  L-Asparagine             0.26                         0.89                            0.34    1.33   0.36    1.30   0.27    1.21   
  L-Histidine              0.30                         1.33                            0.33    1.48   0.34    1.47   0.31    1.42   
  L-Methionine             0.31                         1.39                            0.16    1.16   0.24    1.29   0.09    1.03   
  L-Proline                0.30                         1.35                            0.15    1.13   0.23    1.27   0.10    1.06   
  L-Tryptophan             0.32                         1.39                            0.29    1.41   0.34    1.50   0.22    1.21   
  L-Tyrosine               0.27                         1.29                            0.23    1.26   0.26    1.32   0.15    1.07   
  N-acetyltryptophan       0.32                         1.42                            0.28    1.41   0.33    1.50   0.22    1.23   

12-KetoLCA: 12-ketolithocholic acid; DCA: Deoxycholic acid; GDCA: Glycodeoxycholic acid; GHDCA: Glycohyodeoxycholate; GLCA: Glycolithocholate; LCA: Lithocholic acid; NORDCA: 3α,12α-dihydroxynorcholanate/23-nordeoxycholic acid; TUDCA: Tauroursodeoxycholic acid; UCA: Ursocholic acid; UDCA: Ursodeoxycholic acid.

DISCUSSION
==========

Our MS based metabonomics approach allowed to characterize further metabolite differences between IBD and healthy children, by providing complementary metabolite readouts into the central energy metabolic pathways, bile acids, glutathione and glycine metabolism, which are discussed here after.

Urinary bile acids as metabolic fingerprint of IBD phenotypes
-------------------------------------------------------------

IBD is often associated with some variations in the enterohepatic circulation of bile acids\[[@B2],[@B30],[@B31]\]. Recently, Duboc et al\[[@B30]\] extensively discussed the connections between gut dysbiosis and bile acid metabolism in IBD, and sub-sequent implication for the management of inflammatory conditions. For instance, the alterations in gastrointestinal transit time link to altered bacterial metabolism of primary and secondary bile acids\[[@B32]\]. This is reflected through higher concentrations of conjugated bile acids in the stools from active IBD patients, and concomitant decreased concentrations of secondary bile acids\[[@B30]\]. Bile acid malabsorption has also been reported in children with CD\[[@B33]\]. In our study, we report higher urinary excretion of taurohyocholic acid (THCA, a product of TCDCA metabolism by CYP3A4), ursodeoxycholic acid (UDCA, a product of CDCA by the gut microbiota and the liver), tauroursodeoxycholic acid (TUDCA, a taurine conjugate of UCDA), and βUCA. This signature most likely reflects the alteration of the bile acid metabolism in the digestive tract, as well as modulation of the metabolism of the secondary bile acids by the liver. Previous reports showed an alteration in most circulating bile acids in CD and UC patients\[[@B31]\]. In particular, UC patients were reported with higher amount of LCA and DCA, two secondary bile acids, which may relate to their higher urinary excretion in the urine as noted here. We also observed a strong association between BMI *z*-scores and urinary levels in several bile acids, a trend that was previously reported as well in plasma in other cohort studies\[[@B34]\]. Interestingly, the secondary bile acids UDCA and TUDCA are associated with the lower BMI z-score, whilst bacterial metabolites hippurate and 3-hydroxyphenylacetate are positively associated with the higher ones. Considering IBD children have overall higher urinary UDCA and TUDCA, lower urinary hippurate and 3-hydroxyphenylacetate, and lower BMI *z*-scores, the signature may be reflecting a higher degree of gastrointestinal deregulations with IBD.

Pediatric IBD patients have altered urinary excretion of signaling molecules
----------------------------------------------------------------------------

Pediatric IBD patients also showed a higher urinary loss in dopamine, gamma-aminobutyric acid (GABA) and homogentisic acid. This pattern may be reflecting a disbalance in serotonin - dopamine metabolism, which is being studied in patient with CD\[[@B35]\]. Recent evidences tend to describe excessive synthesis with associated increased tissue levels of serotonin, leading to a perturbation of the molecular homeostasis with dopamine and catecholamines. In particular, a genetic defect of the OCTN1 and OCTN2 of the colon has been identified in patients with CD, resulting in altered transportation of monoamines of the serotonin-dopamine system and their precursors\[[@B35]\]. The higher concentration in dopamine, closely related to higher levels of homogentisic acid (another product of tyrosine metabolism) may reflect this disbalance, yet serotonin metabolism could not be captured with our analytical approach in urine. Furthermore, the higher urinary loss of GABA may be reflecting the higher activity in the TCA cycle towards alpha-ketoglutarate (AKG) and glutamate, and altered colonic epithelial cell metabolism of serotonin-dopamine\[[@B36]\].

IBD in pediatric populations links to perturbations in glycine metabolism
-------------------------------------------------------------------------

Another feature identified in the studied population is the occurrence of higher urinary levels of several metabolites involved in the glutathione metabolism, including pyroglutamic acid (PGA), glutamic acid, glycine and cysteine, which were significantly higher in IBD children in the course of the study. Since PGA is linked to glutathione turnover, the urinary pattern may reflect the higher requirement of the metabolism in glutathione to cope with oxidative stress and immune status\[[@B37],[@B38]\]. In particular, higher urine PGA may indicate higher glutathione need concomitant to diminished glutathione utilization and/or deficient glutathione resynthesis. The higher urinary loss of cysteine, glycine and glutamic acid, the three main precursors for glutathione synthesis provides additional evidence that glutathione cannot optimally be resynthesized, and therefore is broken down and excreted in the urine via its constituent parts such as PGA. The observation of PGA may also point towards glycine deficiency\[[@B39]\], whilst the higher urinary excretion of many essential and non-essential amino acid mainly reflected higher protein breakdown related to higher metabolic requirements in IBD children. However, no statistically significant associations could be found between urinary metabolites and inflammatory endpoints (*e.g*., CRP, EST, calprotectin).

Moreover, it is well described, how before entering the urea cycle, glycine can be conjugated with benzoic acid to form hippurate, and be subsequently excreted in urine. An alternative pathway to excrete ammonia excess is through AKG to glutamic acid, glutamine and phenylacetylglutamine (PAG), which then exits the body via the urine. Glycine deficiencies would increase the demands on the urea cycle and the glutamate/AKG pathways. Moreover, the lower hippurate production may reflect this deficiency in glycine for specific metabolic processes. Previous studies reported that altered hippurate metabolic profile in IBD patients was not directly explain by variations in dietary intake or a deficit in the conjugation of benzoate to glycine in the kidney\[[@B40]\]. Moreover, our analysis describes a higher urinary excretion of salicyluric acid, a glycine conjugate of salicylic acid produced in the kidney via a pathway very similar to that of hippurate, suggesting selective requirement in glycine for metabolic functions. We previously discussed in the context of IBD\[[@B14]\], that carbamyl phosphate synthetase (CAD) - rate-limiting enzyme for the urea cycle - was identified as negative regulator of NOD2 and might be a pharmacologic target for CD therapies\[[@B41]\]. Our observations may provide additional evidence on the essential role of this pathway in case of higher metabolic requirements for glycine associated to malnutrition, higher requirement for glutathione, phase II metabolism and/or growth and development in pediatric populations.

Children with IBD show different energy and protein metabolic requirements
--------------------------------------------------------------------------

We previously reported and discussed how the pediatric IBD patients show the typical phenotype associated with growth failure and body weight loss\[[@B6],[@B14],[@B42]\]. In particular, we reported that our CD pediatric patients showed lower *z*-scores for body weight, body height, BMI and resting energy expenditure compared to healthy controls, which linked to lower concentrations in IGF-1 and IGFBP-3\[[@B14]\]. Our MS metabolomics approaches provided more detailed insights into the changes in protein and energy metabolites. IBD children showed a significant increase in the urinary content of several closely related intermediates of the TCA cycle (fumarate, isocitrate, 2-hydroxyglutaric acid, methylsuccinic acid). Our previous NMR analysis identified higher urinary PAG in IBD patients, which indicated a different energy metabolic status\[[@B14]\]. PAG is a major nitrogenous metabolite for which synthesis depends on the availability of glutamine, mainly generated in the Krebs cycle from AKG. Therefore the increase in isocitrate (precursor of AKG) may be functionally related to higher metabolic turnover for AKG. Moreover, we noted an increased excretion of a 2-hydroxyglutaric acid (Table [2](#T2){ref-type="table"}), normally in molecular equilibrium with AKG, which brings further evidence for a specific increased metabolic flux towards AKG within TCA cycle. Whilst succinate does not show a significantly increased urinary excretion (in agreement with our previous NMR observations\[[@B14]\]), closely related metabolites, namely methylsuccinate and fumarate, had higher urinary levels which may describe a selective oxidation of aspartate, tyrosine and phenylalanine.

Furthermore, the overall increased excretion in most amino acids and the sulfur containing amino acids cysteine and methionine (Table [2](#T2){ref-type="table"}), indicates a different protein metabolism and handling of nitrogen in pediatric IBD patients when compared to healthy matched controls. Urinary metabolite patterns could be ascribed to body composition parameters, such a BMI, body weight and fat mass. Moreover, most of our IBD patients were in clinical remission, and whilst the patients tend to have lower *z*-scores for body weight, height and BMI at baseline, the higher the BMI *z*-scores during follow-up the better growth catch-up for the patient. We here observed an association between higher BMI z-score and higher urinary content in key intermediates of the TCA cycle, namely succinate and AKG, amino acids (asparagine, histidine, methionine, tyrosine, proline). This signature may be associated with overall changes in protein and energy requirements related to body weight gain. Our observations with BMI *z*-scores are similar to recent observations in blood with the Framingham study\[[@B43]\].

Strengths and weaknesses of the study
-------------------------------------

One main limitation of our study is the small number of subjects. However, the longitudinal design and the use of reference group of age- and gender match healthy children provide novel insights into childhood metabolic status in relation to growth and disease.

Future developments
-------------------

We demonstrate that a direct analysis of urine - a biological sample that can be collected non-invasively and in a repeatable fashion - using targeted MS based metabonomics might provide metabolic insights complementary to more invasive blood and stool metabolic analysis, whilst offering an opportunity to monitor the metabolic status in relation to disease state. Here, we identified a peculiar metabolite signature related to bile acids, central energy and glutathione biochemical pathways, which should be further followed up in future studies.
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COMMENTS
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Background
----------

The prevalence of inflammatory bowel disease (IBD) has been increasing over the year, with 25% of the population developing the disease during childhood and adolescence. In the pediatric population, in addition to the clinical and immunological features of the disease, patients suffer of additional growth failure and delayed puberty.

Research frontiers
------------------

There is a great lack of knowledge on how to address metabolic and nutritional requirements in children and adolescents. It is envisioned that the use of omics technologies can generate a system view of metabolic processes associated with the growth and the development of children in relation to the changing physiology. Metabonomics is a promising approach to explore physiological regulatory processes in human clinical research.

Innovations and breakthroughs
-----------------------------

In the present study, they applied targeted mass spectrometry based metabolite profiling to explore bile acids and host-gut microbial metabolites in urine samples from IBD and healthy matched children. Metabolic differences encompass central energy, amino acids, and bile acid metabolism. The authors showed that non-invasive urine bile acid profiling reflect altered hepatic and intestinal barrier dysfunctions, as previously reported through blood or stool metabolic profiling. Moreover, levels of pyroglutamic acid, glutamic acid, glycine and cysteine were significantly higher in IBD children in the course of the study. This suggests that glutathione cannot be optimally synthesized and replenished, rather it is broken down to its constituent parts and excreted through the urine. In addition, a perturbation of the urinary levels of several glycine conjugated metabolites, may associate with differential metabolic requirements in children.

Applications
------------

Non-invasive sampling of urine followed by targeted MS-based metabonomic analysis might elucidate and monitor the metabolic status of children in relation to disease state.

Peer-review
-----------

The excellent study gives a very good data set reflecting metabonomics in IBD children. Understanding the metabolic characteristics of pediatric patients with IBD compared to control is a key factor in diagnosis. The authors stuck to their specific hypothesis and eloquently presented their material. This opens the door for future trials looking at predictive modeling utilizing metabolomics and modifying various therapies to target patients with specific metabolic characteristics.
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